Summit Historical Income Statement
| SMMT Stock | USD 18.46 0.48 2.53% |
Historical analysis of Summit Therapeutics income statement accounts such as Other Operating Expenses of 94.2 M, Research Development of 62.4 M, EBITDA of 1.1 M or Cost Of Revenue of 1.9 M can show how well Summit Therapeutics PLC performed in making a profits. Evaluating Summit Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Summit Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Summit Therapeutics PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Summit Therapeutics PLC is a good buy for the upcoming year.
Summit |
About Summit Income Statement Analysis
Summit Therapeutics PLC Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Summit Therapeutics shareholders. The income statement also shows Summit investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Summit Therapeutics Income Statement Chart
Add Fundamental
Minority Interest
Minority Interest is the portion of a subsidiary corporation stock that is not owned by the parent corporation. The magnitude of the minority interest in the subsidiary company is generally less than 50% of outstanding shares, otherwise the corporation would generally cease to be a subsidiary of the parent. Minority Interest can also be called non-controlling interest.All shareholders of Summit Therapeutics PLC whose combined shares represent less than 50% of the total outstanding shares issued by Summit Therapeutics have a minority interest in Summit Therapeutics.Most accounts from Summit Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Summit Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Summit Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. At this time, Summit Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Interest Expense is likely to gain to about 17.3 M in 2024, despite the fact that Operating Income is likely to grow to (85.2 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 281K | 4.4M | 16.5M | 17.3M | Depreciation And Amortization | 2.5M | 2.5M | 90.7M | 95.3M |
Summit Therapeutics income statement Correlations
Click cells to compare fundamentals
Summit Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Summit Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 524K | 2.0M | 2.5M | 2.5M | 90.7M | 95.3M | |
| Interest Expense | 41.8K | 255K | 281K | 4.4M | 16.5M | 17.3M | |
| Selling General Administrative | 9.3M | 19.2M | 23.6M | 26.7M | 30.3M | 31.8M | |
| Total Revenue | 56.4M | 43.0M | 860K | 1.8M | 704.3K | 0.0 | |
| Gross Profit | 43.0M | 860K | 1.8M | (1.8M) | (2.1M) | (1.9M) | |
| Other Operating Expenses | 39.2M | 53.2M | 88.0M | 64.3M | 89.7M | 94.2M | |
| Operating Income | 15.2M | (53.2M) | (86.2M) | (72.1M) | (89.7M) | (85.2M) | |
| Ebit | 15.2M | (39.1M) | (86.2M) | (55.1M) | (89.7M) | (85.2M) | |
| Research Development | 39.2M | 53.3M | 85.4M | 52.0M | 59.5M | 62.4M | |
| Ebitda | 15.7M | (37.1M) | (83.7M) | (52.6M) | 1.0M | 1.1M | |
| Cost Of Revenue | 97.7K | 24.9K | 199.5K | 2.5M | 2.1M | 1.9M | |
| Total Operating Expenses | (39.2M) | 53.2M | 88.0M | 64.3M | 87.7M | 92.1M | |
| Income Before Tax | 5.0M | (52.9M) | (88.6M) | (78.8M) | (615.9M) | (585.1M) | |
| Total Other Income Expense Net | (10.2M) | (14.0M) | (2.4M) | (19.1M) | (526.1M) | (499.8M) | |
| Net Income | 5.0M | (52.7M) | (86.1M) | (74.4M) | (614.9M) | (584.2M) | |
| Income Tax Expense | (3.8M) | (213K) | (2.5M) | (4.4M) | (946K) | (993.3K) | |
| Net Income Applicable To Common Shares | (24.0M) | (52.7M) | (88.6M) | (78.8M) | (70.9M) | (67.4M) | |
| Tax Provision | (5.3M) | (3.3M) | (213K) | (21K) | (24.2K) | (25.4K) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.